This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Juvidex

Inspired Capital plc

Drug Names(s): Mannose-6-Phosphate (M6P)

Description: Juvidex, a formulation of Mannose-6-Phosphate (M6P), inhibits the activation ofTGF-beta1 and TGF-beta2, which are present at high levels in adult wounds that scar.

Deal Structure: In May 2002, BTG announced BTG exclusively licensed a mannose-6-phosphate technology to Renovo Ltd. BTG received a signature payment for the worldwide licence, with milestone payments expected as the compound completes various development stages. Royalties from sales of the final product, expected to be a scar prevention agent, will be due upon market launch.

Partners: BTG plc


Juvidex News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug